Table 1.

Serum levels of IgA anti-IgG2a RF and development of glomerular lesions in BALB/c mice implanted with 6-19 IgA RF–secreting transfectoma cells

IgAa	Micea	IgA Anti-IgG2a (μg/ml)b	IgA-IgG2a Immune Complex (OD)c	BUN (mg/dl)d	Incidence of Glomerular Lesions (n/n)e
6-19	WT	397.4±30.2	0.365±0.039	39.0±3.9	10/10
	Ig−/−	475.4±53.2	NT	24.5±1.6	0/12
	C3−/−	358.0±52.8	NT	23.0±0.9	0/12
46-42	WT	626.3±27.4	0.528±0.062	27.3±2.0	0/15

Values expressed with a plus/minus sign are the mean ± SEM. WT, wild type.

^a10⁷ 6-19 or 46-42 IgA RF–secreting cells were inoculated intraperitoneally into 2-month-old WT, immunoglobulin- or C3-deficient BALB/c mice.

^bSerum levels of IgA anti-IgG2a RF 3 weeks after implantation of 6-19 or 46-42 IgA RF–secreting cells, expressed as μg/ml (mean of 10–15 mice ± SEM; pooled results from 2–3 independent experiments with 5–7 mice per group for each experiment). Serum levels of IgA anti-IgG2a before injection of cells were less than 1 μg/ml.

^cSerum levels of IgA-IgG2a immune complexes 3 weeks after implantation of 6-19 or 46-42 IgA RF–secreting cells, expressed as OD at 405 nm (mean of 10 mice ± SEM). Serum levels of IgA-IgG2a immune complexes before injection of cells were 0.079±0.005.

^dSerum levels of BUN 3 weeks after implantation of 6-19 or 46-42 IgA RF–secreting cells, expressed as mg/dl (mean of 7–10 mice ± SEM). Serum levels of BUN before injection of cells were 22.6±2.1 mg/dl.

^eAs evaluated by histologic examination.